Key facts
- Notable investors include Japan External Trade Organization, Japan Finance Corporation, Intellectual Property Acceleration Program for Startups, Gx Partners, MURC Accelerator LEAP OVER — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Hynts Tech
- ·The full record, as it builds
Funding rounds
No funding rounds for Hynts Tech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hynts Tech
Developer of nanotechnology-based systems designed for cellular material transfer and extraction. The company's platform integrates advanced membrane stamping technology, automated cell processing capabilities, macromolecule delivery, and reproducibility-focused design, enabling research institutions and biotechnology organizations to accelerate gene editing workflows, improve precision in regenerative medicine, and streamline complex cell therapy processes through scalable and reliable solutions.
- Sector
- Healthcare
- HQ
- Kitakyushu, Japan
- Founded
- 2021
- Employees
- 10
- Website
- hyntstech.com/
- Ownership
- Privately Held (backing)
Hynts Tech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hynts Tech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hynts Tech in its N-PORT filings yet. We sweep new filings monthly.